TrivarX Partners with Beyond Drug Development to Advance Novel MRI-Based Cancer Imaging Technology
核心洞察
TrivarX (搜索) has engaged specialist contract research organization Beyond Drug Development (搜索) to support the planned Phase 1 safety trial for its proprietary Stabl-Im (搜索) oncology (搜索) imaging technology.
Stabl-Im (搜索) is an innovative MRI-based functional imaging platform that visualizes actively replicating tumor (搜索) cells using stable isotopes without radioactive tracers.
The Phase 1 safety study is targeted to commence in the second half of 2026, evaluating safety and tolerability in healthy volunteers through oral dosing.
TrivarX (搜索) has engaged specialist contract research organization Beyond Drug Development (搜索) to support the planned Phase 1 safety trial for its proprietary Stabl-Im (搜索) oncology (搜索) imaging technology. The partnership will advance clinical protocol completion, supporting clinical and regulatory documentation and clinical site selection activities as the company prepares for its first-in-human study.
Novel Imaging Platform Targets Cancer Diagnostics Gap
Stabl-Im (搜索) represents an innovative MRI-based functional imaging platform designed to visualize actively replicating tumor (搜索) cells using stable isotopes without the need for radioactive tracers. The technology aims to provide earlier and more biologically meaningful insight into tumor activity, cellular proliferation, and treatment response compared to existing imaging methods.
TrivarX (搜索) is targeting commencement of the Phase 1 safety study during the second half of calendar year 2026 to evaluate the safety and tolerability of Stabl-Im (搜索) in healthy human volunteers following oral dosing. The initial Phase 1 study is expected to be an open-label sequential-cohort trial that generates human safety and tolerability data ahead of later efficacy work.
Strategic Partnership with Experienced CRO
Beyond Drug Development (搜索) is a boutique therapeutic product development consultancy and contract research organization focused on early-phase development for biotechnology and pharmaceutical companies. The group provides strategic, regulatory, and clinical development support across innovative therapeutic and diagnostic programs.
Beyond's team has an average of more than 20 years' experience, including access to specialist regulatory toxicology expertise with more than 30 years of experience supporting therapeutic and imaging product development programs. The appointment gives TrivarX (搜索) external clinical development support as Stabl-Im (搜索) moves from planning toward first-in-human assessment.
Clinical Development Milestone
Incoming chief executive officer Dr. Danielle Meyrick said the engagement marked an important development milestone for the Stabl-Im (搜索) program. "Having worked with the group previously, I know firsthand that Beyond brings highly relevant expertise across early-phase clinical development, regulatory strategy, and imaging product advancement, which positions the program strongly as we progress toward commencement of the Phase 1 safety study," Dr. Meyrick said.
The Phase 1 study is intended to support progression toward Phase 2 efficacy studies and broader clinical imaging applications. Dr. Meyrick said the human safety and tolerability data would form a key step toward broader clinical development and commercialization initiatives, and that Stabl-Im (搜索)'s use of stable isotope imaging could create a differentiated position in oncology (搜索) diagnostics.
"With protocol development and broader planning activities now underway, we remain focused on progressing the study toward commencement before the end of CY2026," she added.